# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC Capital analyst Gregory Renza downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Outperform to Sector Perform and lowers...
HC Wainwright & Co. analyst Andrew Fein downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Neutral and lowers the...
Leerink Partners analyst Joseph Schwartz downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Outperform to Market Perform and...
B of A Securities analyst Tazeen Ahmad downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Neutral to Underperform and lowers...
Stifel analyst Dae Gon Ha downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and lowers the price target from $2...
Fulcrum Therapeutics stock drops after Phase 3 REACH trial of losmapimod flops in Facioscapulohumeral Muscular Dystrophy. The c...